Electronic cigarettes

Controversy and dispute

  • Laura Llambí Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Clínica Médica “A”. Prof. Agda. Unidad de Tabaquismo. Responsable
  • Carolina Parodi Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Clínica Médica “A”. Asistente. Con funciones en Unidad de Tabaquismo
  • Mary Barros Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Departamento de Psicología Médica. Asistente. Licenciada. Con funciones en Unidad de Tabaquismo
  • Antonella Pippo Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Clínica Médica “A”. Residente

Abstract

Electronic nicotine delivery systems, also known as electronic cigarettes (EC), are devices designed to emulate traditional cigarettes and administer nicotine by inhalation, vaporized, without tobacco combustion. They began to be marketed in China in 2006, and since 2009 they are widely available in the world. In Uruguay, current regulations prohibit its commercialization, although many Uruguayans have bought EC abroad.
Its use as a harm reduction tool in those individuals who do not wish to quit smoking or as a therapeutic for cessation has generated a growing debate in the scientific community dedicated to tobacco control.

References

(1) Palazzolo DL. Electronic Cigarettes and Vaping: a New Challenge in Clinical Medicine and Public Health. A Literature Review. Front Public Health 2013; 1:56. eCollection 2013. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859972/. Consulta: abril 2014.
(2) Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control 2014; 23(2):133-9.
(3) Burstyn I. Peering through the mist: systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 2014;14:18. Disponible en: http://www.biomedcentral.com/1471-2458/ 14/18. Consulta: abril 2014.
(4) Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013; 382(9905):1629-37.
(5) Gilmore AB, Peeters S. Understanding corporations to inform public health policy: the example of tobacco industry interests in harm reduction and reduced risk products. Lancet 2013; 382 (Suppl 3):S14.
Published
2014-06-30
How to Cite
1.
Llambí L, Parodi C, Barros M, Pippo A. Electronic cigarettes. Rev. Méd. Urug. [Internet]. 2014Jun.30 [cited 2024Nov.25];30(2):137-8. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/253
Section
Letters to the Editor